Report

Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast

  • Publish Date: Mar,2022
  • Report ID: QI036
  • Page : 237
  • Report Type : PDF (Email)
Chapter 1. Research Framework
1.1. Objective
1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions
1.3. Research Methodology
1.3.1. List of Primary & Secondary Sources
1.3.2. Market Size Estimation
1.3.2.1. Assumption for the Study
1.3.2.2. Data Triangulation
Chapter 2. Executive Summary: Global Respiratory Syncytial Virus Market
Chapter 3. Global Respiratory Syncytial Virus Market Overview
3.1. Industry Value Chain Analysis
3.1.1. Formulation
3.1.2. Processing and Packaging
3.1.3. Distributors
3.1.4. End Users
3.2. Industry Outlook
3.2.1. Epidemiology and Patient Population
3.2.1.1. Key Findings
3.2.1.2. Epidem and Market Methodology
3.2.1.3. 8MM Incident Patient Population of Respiratory Syncytial Virus
3.2.2. Country Wise-Epidemiology of Respiratory Syncytial Virus
3.2.2.1. United States Epidemiology
3.2.2.1.1. Assumptions and Rationale
3.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus in the United States
3.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus in the United States
3.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus in United States
3.2.2.1.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the United States
3.2.2.2. EU5 Epidemiology
3.2.2.2.1. Germany
3.2.2.2.1.1. Assumptions and Rationale
3.2.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus in Germany
3.2.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus in Germany
3.2.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus in Germany
3.2.2.2.1.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in Germany
3.2.2.2.2. France
3.2.2.2.2.1. Assumptions and Rationale
3.2.2.2.2.2. Total Incident Cases of Respiratory Syncytial Virus in France
3.2.2.2.2.3. Case-Specific Incidence of Respiratory Syncytial Virus in France
3.2.2.2.2.4. Age-Specific Incidence of Respiratory Syncytial Virus in France
3.2.2.2.2.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in France
3.2.2.2.3. Italy
3.2.2.2.3.1. Assumptions and Rationale
3.2.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus in Italy
3.2.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus in Italy
3.2.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus in Italy
3.2.2.2.3.5. Incident of Respiratory Syncytial Virus by Extremities (%) in Italy
3.2.2.2.4. Spain
3.2.2.2.4.1. Assumptions and Rationale
3.2.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus in Spain
3.2.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus in Spain
3.2.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus in Spain
3.2.2.2.4.5. Incident of Respiratory Syncytial Virus by Extremities (%) in Spain
3.2.2.2.5. United Kingdom
3.2.2.2.5.1. Assumptions and Rationale
3.2.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus in the United Kingdom
3.2.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus in the United Kingdom
3.2.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus in the United Kingdom
3.2.2.2.5.5. Incident of Respiratory Syncytial Virus by Extremities (%) in the United Kingdom
3.2.2.3. Japan Epidemiology
3.2.2.3.1. Assumptions and Rationale
3.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus in Japan
3.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus in Japan
3.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus in Japan
3.2.2.3.5. Incident of Respiratory Syncytial Virus by Extremities (%) in Japan
3.2.2.4. China Epidemiology
3.2.2.4.1. Assumptions and Rationale
3.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus in China
3.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus in China
3.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus in China
3.2.2.4.5. Incident of Respiratory Syncytial Virus by Extremities (%) in China
3.2.2.5. India Epidemiology
3.2.2.5.1. Assumptions and Rationale
3.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus in India
3.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus in India
3.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus in India
3.2.2.5.5. Incident of Respiratory Syncytial Virus by Extremities (%) in India
3.2.3. Treatment and Management of Respiratory Syncytial Virus
3.2.3.1. Scope of Treatment
3.2.3.2. Treatment Guidelines
3.2.3.2.1. American Academy of Pediatrics guidelines for Respiratory Syncytial Virus
3.2.4. Unmet Needs
3.2.5. Marketed Drugs
3.2.5.1. Synagis (Palivizumab): MedImmune/Abbott Laboratories Inc.
3.2.5.1.1. Product Description
3.2.5.1.2. Regulatory Milestones
3.2.5.1.3. Clinical Development
3.2.5.1.4. Ongoing Current Pipeline Activity
3.2.5.1.5. Safety and efficacy
3.2.5.1.6. Product Profile
3.2.5.2. Virazole (Ribavirin): ICN Pharmaceuticals
3.2.5.2.1. Regulatory Milestones
3.2.5.2.2. Clinical Development
3.2.5.2.3. Ongoing Current Pipeline Activity
3.2.5.2.4. Safety and efficacy
3.2.5.2.5. Product Profile
3.2.6. Emerging Drugs
3.2.6.1. EDP 938: Enanta Pharmaceuticals
3.2.6.1.1. Product Description
3.2.6.1.2. Other Development Activities
3.2.6.1.3. Clinical Development
3.2.6.1.4. Clinical Trials Information
3.2.6.1.5. Safety and Efficacy
3.2.6.1.6. Product Profile
3.2.6.2. Nirsevimab: AstraZeneca
3.2.6.2.1. Product Description
3.2.6.2.2. Other Development Activities
3.2.6.2.3. Clinical Development
3.2.6.2.4. Clinical Trials Information
3.2.6.2.5. Safety and Efficacy
3.2.6.2.6. Product Profile
3.2.6.3. MEDI8897: MedImmune LLC
3.2.6.3.1. Product Description
3.2.6.3.2. Other Development Activities
3.2.6.3.3. Clinical Development
3.2.6.3.4. Clinical Trials Information
3.2.6.3.5. Safety and Efficacy
3.2.6.3.6. Product Profile
3.2.6.4. JNJ-53718678: Janssen Sciences Ireland UC
3.2.6.4.1. Product Description
3.2.6.4.2. Other Development Activities
3.2.6.4.3. Clinical Development
3.2.6.4.4. Clinical Trials Information
3.2.6.4.5. Safety and Efficacy
3.2.6.4.6. Product Profile
3.2.7. Target population and RSV vaccine
3.2.7.1. Maternal
3.2.7.2. Infants
3.2.7.3. Children
3.2.7.4. Elderly
3.2.8. RSV Vaccines in pipeline
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Dynamics and Trends
3.5.1. Key Trends
3.5.2. Growth Drivers
3.5.3. Restraints/ Challenges
3.6. Market Growth and Outlook
3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2017-2027
3.6.2. Pricing Analysis
3.7. Covid-19 Impact Assessment on Market Growth Trend
3.7.1. Growth Trend Shift Analysis
3.7.2. Industry Best Practices
3.8. Regulatory Landscape
Chapter 4. Competition Dashboard
4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2020
4.3. Competitor Mapping
Chapter 5. Respiratory Syncytial Virus Market Analysis, By Drug type
5.1. Key Insights
5.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
5.2.1. Ribavirin
5.2.2. Synagis
5.2.3. Virazole
5.2.4. Palivizumab
5.2.5. Riba Tab
5.2.6. Others
Chapter 6. Respiratory Syncytial Virus Market Analysis, By Dosage Form
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
6.2.1. Oral
6.2.2. Injectable
6.2.3. Inhaler
6.2.4. Others
Chapter 7. Respiratory Syncytial Virus Market Analysis, By Treatment Type
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
7.2.1. Immune prophylaxis
7.2.2. Supportive care
7.2.3. Antiviral Medications
Chapter 8. Respiratory Syncytial Virus Market Analysis, By Distribution Channel
8.1. Key Insights
8.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
8.2.1. Hospital pharmacies
8.2.2. Drug Stores
8.2.3. Retail pharmacies
8.2.4. Clinics
Chapter 9. Respiratory Syncytial Virus Market Analysis, By Region/Country
9.1. Key Insights
9.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
9.2.1. North America
9.2.1.1. The U.S.
9.2.1.2. Canada
9.2.1.3. Mexico
9.2.2. Europe
9.2.2.1. The UK
9.2.2.2. Germany
9.2.2.3. France
9.2.2.4. Italy
9.2.2.5. Spain
9.2.2.6. Poland
9.2.2.7. Russia
9.2.2.8. Rest of Europe
9.2.3. Asia Pacific
9.2.3.1. China
9.2.3.2. India
9.2.3.3. Japan
9.2.3.4. Australia & New Zealand
9.2.3.5. ASEAN
9.2.3.6. Rest of Asia Pacific
9.2.4. Middle East & Africa
9.2.4.1. UAE
9.2.4.2. Saudi Arabia
9.2.4.3 South Africa
9.2.4.4 Rest of MEA
9.2.5. South America
9.2.5.1. Argentina
9.2.5.2. Brazil
9.2.5.3. Rest of South America
Chapter 10. North America Respiratory Syncytial Virus Market Analysis
10.1. Key Insights
10.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
10.2.1. By Drug type
10.2.2. By Dosage form
10.2.3. By Treatment type
10.2.4. By Distribution channel
10.2.5. By Country
Chapter 11. Europe Respiratory Syncytial Virus Market Analysis
11.1. Key Insights
11.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
11.2.1. By Drug type
11.2.2. By Dosage form
11.2.3. By Treatment type
11.2.4. By Distribution channel
11.2.5. By Country
Chapter 12. Asia Pacific Respiratory Syncytial Virus Market Analysis
12.1. Key Insights
12.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
12.2.1. By Drug type
12.2.2. By Dosage form
12.2.3. By Treatment type
12.2.4. By Distribution channel
12.2.5. By Country
Chapter 13. Middle East & Africa Respiratory Syncytial Virus Market Analysis
13.1. Key Insights
13.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
13.2.1. By Drug type
13.2.2. By Dosage form
13.2.3. By Treatment type
13.2.4. By Distribution channel
13.2.5. By Country
Chapter 14. South America Respiratory Syncytial Virus Market Analysis
14.1. Key Insights
14.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
14.2.1. By Drug type
14.2.2. By Dosage form
14.2.3. By Treatment type
14.2.4. By Distribution channel
14.2.5. By Country
Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
15.1. AbbVie, Inc.
15.2. AstraZeneca PLC
15.3. Atea Pharmaceuticals
15.4. Bausch Health Companies Inc.
15.5. Celltrion Inc.
15.6. Enanta Pharmaceuticals, Inc
15.7. F. Hoffmann-La Roche AG
15.8. Gilead Sciences, Inc.
15.9. GlaxoSmithKline PLC
15.10. Johnson & Johnson's
15.11. mAbxience
15.12. Medivir AB
15.13. Merck Co., Inc.
15.14. Pfizer Inc.
15.15. ReViral Ltd.
15.16. Sanofi
15.17. Teva Pharmaceutical Industries Ltd.
15.18. Other Prominent Players